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INTRODUCTION
Medical researchers perpetually aspire to a future where an
individual's genes will chart the way for the identification and
prescription of the right lifesaving drug. The drug will be tailored to
a patient's specific genetic profile, assuring that the drug will work
safely and effectively for that patient. During the course of care, a
physician will extract a biological sample from the patient, run it
*Professor of Law, Loyola University Chicago School of Law (jparadise@luc.edu). This
article was developed for the New York University Journal of Law & Liberty and the
NYU School of Law Classical Liberal Institute's Medical Innovation and the Law
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through a diagnostic test, and the test results, along with the patient's
medical history, will guide the medical decision on which drug to
prescribe. Such an integrative process eliminates the potential for
that patient to experience devastating adverse drug events because
the drug is not safe or because the treatment is ineffective (and
assuredly expensive). Such a future provides benefits not only to the
patient but also to countless entities and actors within the public
health and medical enterprise.
This scenario may be coming closer to fruition as research
initiatives and public support for the field of precision medicine gain
momentum. The National Institutes of Health (NIH) describes
precision medicine as "an emerging approach for disease treatment
and prevention that takes into account individual variability in
genes, environment, and lifestyle for each person."' President Obama
initially channeled $215 million into the Precision Medicine Initiative
(PMI), with funds to the NIH and the Food and Drug Administration
(FDA) "to accelerate biomedical discoveries and provide clinicians
with new tools, knowledge, and therapies to select which treatments
will work best for which patients." 2 In remarks at the White House
East Room, Obama touted precision medicine as "delivering the right
treatments at the right time, every time to the right person." 3 The 21st
1 LIsTER HILL NATIONAL CENTER FOR BIOMEDICAL COMMUNICATIONS, DEP'T OF HEALTH
AND HUMAN SERVS., HELP ME UNDERSTAND GENErIcS: PRECISION MEDIcINE 3 (2017),
https://ghr.nlm.nih.gov/primer/precisionmedicine.pdf.
2 Press Release, White House, Office of the Press Secretary, Fact Sheet: President
Obama's Precision Medicine Initiative (lan. 30, 2015), https://obamawhitehouse
.archives.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-
medicine-initiative [hereinafter Fact Sheet].
3 Press Release, White House, Office of the Press Secretary, Remarks by the President
on Precision Medicine (Jan. 30, 2015), https://obamawhitehouse.archives.gov/the-
press-office/2015/01/30/remarks-president-precision-medicine.
Imaged with Permission of N.Y.U. Journal of Law & Liberty
673
New York University Journal of Law & Liberty [Vol. 11:672
Century Cures Act, signed into law on December 13, 2016, further
supports the PMI and related research with a $4.8 billion pledge over
the next ten years.4
The push for precision in the drug context is not new. The PMI
and the field of precision medicine build on decades of genomic
research and the successful sequencing of the human genome. Many
terms have evolved to describe the concept of harnessing genomic
information to guide the development of diagnostics and treatment
for individuals or subpopulations of patients: pharmacogenomics,
personalized medicine, targeted medicine, and most recently,
precision medicine.' The PMI emphasizes the need for collaborations
4 21st Century Cures Act, Pub. L. No. 114-255,130 Stat. 1033 (codified throughout titles
15,21, 26,28, 29,34, and 42 of the U.S.C.); Press Release, U.S. House of Representatives
Comm. on Energy and Commerce, The 21st Century Cures Act Fact Sheet,
https://energycommerce.house.gov/sites/republicans.energycommerce.house.gov/
files/documents/114/analysis/20161128%20Cures%20Fact%20Sheet.pdf (last visited
Oct. 5, 2017) [hereinafter Committee on Energy and Commerce].
s This article examines "precision medicine" in the context of the connection between
drug development and genomic information. However, the terms "personalized
medicine" and "precision medicine" encompass not only the use of genomic
information but also other biological functioning or status of an individual for
development of treatments. The FDA offers several examples of personalized
medicine outside of the realm of pharmacogenomics, including a custom-made
tinnitus masker tailored to an individual patient's hearing, pedicle screw spinal
systems assembled according to a patient's anatomy and physiology with the aid of
MRI/CT imaging, and artificial pancreas device systems that monitor glucose levels
and deliver insulin doses based on individual readings for treatment of diabetes. See
U.S. FOOD & DRUG ADMIN., PAVING THE WAY FOR PERSONALIZED MEDICINE: FDA's
ROLE IN A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT 10 (Oct. 2013), https://
www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/
ucm372421.pdf. Recent developments in 3D printing of medical devices are also
examples of personalization (or customization as it is referred in the regulatory
scheme) in medicine. See 3D Printing of Medical Devices, FOOD & DRUG ADMIN.,
https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/3DPrintin
gofMedicalDevices/ default.htm.
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of academic medical centers, researchers, patients and patient
advocates, private foundations, and medical product innovators to
achieve its lofty goals.' Coupled with directives to the FDA within
the 21st Century Cures Act on aspects of the regulatory science,
advancements in precision medicine will introduce fundamental
disruptions to the historical structure, support, and contributions in
drug research and development. Signals from leaders in the drug
industry indicate that there is rapid investment in precision
medicine, nearly doubling over the past five years.'
Moving innovative research in precision medicine into the
medical marketplace will not be easy. Precision medicine poses
challenges to traditional FDA regulatory paradigms. Eventual
downstream medical products will involve both the initial detection
of the presence (or absence) of a specific genetic variant and the
subsequent drug treatment tailored to that genetic variant. This
diagnosis-treatment spectrum necessarily implicates the regulatory
authority of the FDA with regard to both medical devices and new
human drugs and biologics. The success of the PMI will inevitably
increase pressures on a regulatory system already suffering from a
crisis of heavy industry and expert criticism due to its lack of clarity
and transparency. Precision medicine also implicates the ongoing
6 Emerging concerns surrounding the expansion of players in research and
development include the proper role of patient advocate groups, identification and
management of complex conflicts of interest, proper incentive structures, access to and
sharing of research samples and health information, inventor status and patent rights,
payments and contractual agreements, and eventual profit share.
7 Reenita Das, Drug Industry Bets on Precision Medicine: Five Trends Shaping Health Care
Delivery, FORBES (Mar. 8, 2017, 9:35 AM), https://www.forbes.com/sites/reenit
adas/2017/03/08/drug-development-industry-bets-big-on-precision-medicine-5-top
-trends-shaping-future-care-delivery/ #33f972755d3a.
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debate about FDA oversight of laboratory developed tests.8 In a 2013
report assessing scientific promise and related regulatory obstacles,
the FDA acknowledged that precision medicine ushers in a "new era
of medical product development" for the agency; however, then
Commissioner Hamburg emphasized that regulatory adaptation
was a priority.9 With enactment of the 21st Century Cures Act and
other recent legislation, that adaptation may actually be achievable if
the FDA is willing to create flexible, dynamic regulatory approaches
for innovative new products.o
This article surveys the current structure of the FDA regulatory
regime as it impacts precision medicine and specifically explores a
category of FDA-regulated products called companion diagnostics.
Part I discusses the field of precision medicine and its relationship to
companion diagnostics, highlighting the historical background,
incremental funding initiatives, and market trajectory for companion
diagnostic products. Part II discusses the FDA institutional
frameworks for regulation of traditional drug, biologic, and medical
device products, as well as the FDA's approach to companion
8 See generally Laboratory Developed Tests, FOOD & DRUG ADMIN., https://
www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics
/LaboratoryDevelopedTests/default.htm (last updated Jan. 13, 2017).
9 U.S. FOOD & DRUG ADMIN., PAVING THE WAY FOR PERSONALIZED MEDICINE: FDA's
ROLE IN A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT 2 (2013), https://www.
fda.gov/ downloads/ scienceresearch/ specialtopics/ personalizedmedicine/
ucm372421.pdf.
10 1 have previously written about the need for dynamic FDA regulatory models for
emerging technologies. See, e.g., Jordan Paradise et al., The Challenge of Developing
Oversight Approaches to Nanobiotechnology, 37 J. L., MED. & ETICs 543, 543-45 (2009);
Jordan Paradise et al., Evaluating Oversight of Human Drugs and Medical Devices: A Case
Study of the FDA and Implications for Nanobiotechnology, 37 J. L., MED. & ETHICS 598, 598-
624 (2009); Jordan Paradise et al., Developing U.S. Oversight Strategies for
Nanobiotechnology: Learning from Past Oversight Experiences, 37 J. L. MED. & ETHICS 688,
688-705 (2009).
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diagnostics. Part III identifies key legislative and agency activity
supporting innovation in biomedicine, including the Affordable Care
Act of 2010, the FDA Safety and Innovation Act of 2012, the 21st
Century Cures Act of 2016, and FDA policy on laboratory developed
tests. Part III also highlights how these may impact the development
of companion diagnostics and possibly help facilitate regulatory
flexibility. Part IV concludes.
I. GENOMICS, PRECISION MEDICINE, AND COMPANION
DIAGNOSTICS
A. HISTORICAL PERSPECTIVES ON THE GENOME
The moment that the initial three billion base pair sequence of
the human genome was published in 2001, the race to fully realize its
potential in human health and disease had already begun. Decades
of scientific work on the part of countless international cohorts had
gone into the endeavor, and the competition to be the first to succeed
was fierce.II Aptly, the article led by Eric S. Lander begins, "The
human genome holds an extraordinary trove of information about
human development, physiology, medicine and evolution." 12
Likewise, J. Craig Venter proffered that " [d]ecoding of the DNA that
constitutes the human genome has been widely anticipated for the
contribution it will make toward understanding human evolution,
the causation of disease, and the interplay between the environment
1 Two independent teams, one publicly-funded and one privately-funded, published
findings within one day of each other in different journals. Eric S. Lander et al., Initial
Sequencing and Analysis of the Human Genome, 409 NATURE 860 (2001); J. Craig Venter
et al., The Sequence of the Human Genome, 291 SC. 1304 (2001).
12 Lander et al., supra note 11, at 860.
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and heredity in defining the human condition."' 3 By the time the
complete human genome sequence was published in 2004,14 the new
field of pharmacogenomics was fueling tireless research into the
utilization of genomic information to inform drug development and
medical treatment. Combining the field of pharmacology (studying
the mechanisms of action of drugs) and genomics,
pharmacogenomics aims to tailor specific drugs and treatments to an
individual's genetic make-up to maximize safety and efficacy.'
The resulting attention on pharmacogenomics has given rise to a
parade of terms to describe the promise of genomics for medicine,
including personalized medicine, targeted medicine, and, most
recently, precision medicine. The distinctions among these phrases is
unclear at best, as they all envision the ability to make treatment
"precise"; in other words, treatment tailored to an individual or well-
defined group of people sharing particular characteristics. Such an
approach challenges the dominant model of blockbuster drug
development by narrowing the focus of safety and efficacy to a much
smaller, and identifiable, population. The focus on individualization
also has relevant implications regarding financial incentives for
industry to embark on this type of research and development. This
article will use the term precision medicine to encompass these
terms, as the difference, if any, resides only in how individualized
the drug must be to qualify as "precise."
Almost two decades following the initial publications of the
human genome, that "extraordinary trove of information," as
13 Venter et al., supra note 11, at 1305.
14 See International Human Genome Sequence Consortium, Finishing the Euchromatic
Sequence of the Human Genome, 431 NATURE 931 (2004).
15 See Mark A. Rothstein & Phyllis Griffin Epps, Ethical and Legal Implications of
Pharmacogenomics, 2 NATURE REvs. 228, 228 (2001).
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described by Lander, continues to hold promise for innovative and
life-saving contributions to medicine. However, deciphering the
genetic information for its role in drug response has proven more
difficult in practice given the complexity of the human genome.
There are currently only twenty FDA-approved drugs or biologics on
the market that can truly be characterized as pharmacogenomic -
that is, they are tailored specifically to a given genetic profile or
genetic variant that can be identified by a diagnostic test.' 6 The FDA
has cleared or approved several dozen in vitro diagnostic or imaging
tools as medical devices designed to detect whether a given drug or
biologic has a relevant safety or efficacy implication for a particular
genetic make-up; these several dozen tests correspond to the twenty
FDA-approved drugs or biologics." These "companion diagnostics"
that provide important information for the safe and effective use of a
corresponding therapeutic drug or biologic are distinct from wide-
ranging nucleic-acid based tests that are not linked to a particular
drug.
16 See Personalized Medicine and Companion Diagnostics Go Hand in Hand, FooD & DRUG
ADMIN., https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm407328.htm
(last updated Sept. 27, 2017) [hereinafter Hand in Hand].
17 List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools),
U.S. FOOD & DRUG ADMIN., http://www.fda.gov/MedicalDevices/Productsand
MedicalProcedures/InVitroDiagnostics/ucm301431.htm (last updated Aug. 02,2017)
[hereinafter List of Companion Diagnostic Tests]. These biologics and/or drugs are the
following branded or generic products: ado-trastuzumab emtasine, Erbitux
(cetuximab), Exjade (deferasirox), Gleevac (imatinib mesylate), Gilotrif (afatinib),
Herceptin (trastuzumab), Iressa (gefitinib), Keytruda (pembrolizumab), Lynparza
(olaparib), Mekinist (trametenib), Perjeta (pertuzumab), Rubraca (rucaparib), Rydapt
(miidostaurin), Tafinlar (dabrafenib), Tagrisso (osimertinib), Tarceva (erlotinib),
Venclexta (venetoclax), Vectibix (pamtumumab), Xalkori (crizotinib), and Zelboraf
(vemirafenib). Each may have multiple companion diagnostics on the market. Id.
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One early example, which progressed alongside scientific
advancements during the Human Genome Project (HGP), is the
metastatic breast cancer biologic Herceptin (trastuzumab),
manufactured by Genentech. Herceptin was developed for women
with a genetic variant causing the overproduction of the human
epidermal growth hormone receptor 2 protein known as HER2.'"
Approved via biologic license application (BLA) in 1998, Herceptin
is an effective treatment in women for whom the diagnostic test
shows elevated HER2 protein levels at the cancer site.1 9 However, the
biologic is ineffective in women without elevated HER2 levels.
Herceptin and its corresponding diagnostic test developed
collaboratively by DAKO (and approved as a medical device by the
FDA) were approved as the first new biologic with a companion
diagnostic in the United States. 20 There are now ten companion
diagnostic tests on the U.S. market for Herceptin. 21
B. FUNDING INFUSIONS FOR PRECISION MEDICINE
Standing on the shoulders of substantial federal appropriations
for scientific research in the realms of genetics (the HGP),
nanotechnology (National Nanotechnology Initiative), brain
research (BRAIN Initiative), and cancer (Cancer Moonshot 2020), the
Precision Medicine Initiative (PMI) shares many features with each
of these federally-funded projects. At the core of each has been a goal
of fostering multi-disciplinary approaches to research and
development that support medical innovation. The PMI identifies
18 See Hand in Hand, supra note 16.
19 See Id.
20 See Hand in Hand, supra note 16.
21 See List of Companion Diagnostic Tests, supra note 17.
Imaged with Permission of N.Y.U. Journal of Law & Liberty
680
2017] CULTIVATING INNOVATION IN PRECISION MEDICINE
five core objectives: (1) discovery of cancer treatments; (2)
development of a voluntary, national research cohort; (3) robust
privacy protections and interoperability; (4) assessment of regulatory
regimes; and (5) strong partnerships in research. 22 While all
objectives merit attention, this article addresses the issue of
regulatory regimes by surveying the recent legislative landscape
providing a framework for the FDA.
The PMI is underway. Original plans for a PMI Cohort Program
were announced in September 2015, led by NIH Director Francis
Collins, with a budget request of $130 million for NIH. 23 The
program, renamed the All of Us Research Program, proposes to
recruit over a million new participants to submit blood samples for
DNA analysis, undergo a clinical exam, and share their electronic
health record.2 4 The first course of research aims to test participant
DNA for single nucleotide polymorphisms (SNPs) that may indicate
disease risk genes.25 The driver for starting with SNPs, rather than
full genome sequencing, is the cost: $50 per sample versus over
$1,000.26
Federal funding for precision medicine was enhanced with
passage of the 21st Century Cures Act. The 21st Century Cures Act
appropriates $4.8 billion in funding to the NIH for the PMI over the
22 Fact Sheet, supra note 2.
2 THE PRECISION MED. INITIATIVE COHORT PROGRAM, NAT'L INSTS. OF HEALTH,
PRECISION MED. INITIATIVE (PMI) WORKING GROUP REPORT TO THE ADVISORY
COMMnITEE TO THE DIRECTOR 9 (2015), https://acd.od.nih.gov/documents/reports
/PIWG-report_2015-09-17-Final.pdf.
24 Jocelyn Kaiser, NIH Opens Precision Medicine Study to Nation, 349 SCI. 1433, 1433
(2015). See All of Us Research Program, NATL INSTS. OF HEALTH, https://www.
nih.gov/research-training/allofus-research-program (last visited Sept. 28, 2017).
25 Kaiser, supra note 24.
26 Id.
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next decade.2 7 It remains to be seen how the Trump Administration
and Congress will allocate funding; the President's original proposed
budget for 2017 included a $12.6 billion budget decrease to HHS and
$5.8 billion in cuts to NIH. 28 Subsequent Congressional action
assured a $2 billion increase in 2017 for NIH, including additional
money for the PMI. 29 Executive Orders and the federal hiring freeze
also contribute uncertainty as to the long-term implementation of the
legislation,3 0 though many remain hopeful that the allocated funds
will be appropriated for 2018 and beyond."
Along with targeted funding, the 21st Century Cures Act
establishes an organizational framework for the PMI, including
authority to the Secretary of the Department of Health and Human
Services (HHS) to implement the initiative. The Act amends the
Public Health Service Act to "augment efforts to address disease
prevention, diagnosis, and treatment." 32 The Act establishes the
2 21st Century Cures Act, Pub. L. No. 114-255, § 1001, 130 Stat. 1033 (codified
throughout titles 15, 21, 26, 28, 29, 34, and 42 of the U.S.C.); United States House of
Representatives Committee on Energy and Commerce, supra note 4.
2 Tal Kopan, Here's What Trump's Budget Proposes to Cut, CNN (Mar. 16,2017,1:21 PM),
http://www.cnn.com/2017/03/16/politics/trump-budget-cuts/.
29 Press Release, U.S. Senate Comm. on Appropriations, Labor, Health and Human
Servs., and Educ. and Related Agencies Appropriation Bill 2017: Omnibus Agreement
Summary, https://www.appropriations.senate.gov/imo/media/doc/FY17%20
Labor%20HHS%20Education%20Conference%2OAgreement%2OSummary%20-
%20Final.pdf (last visited Sept. 28, 2017).
* Seth D. Rothman & Jessica Studness, FDA Faces Uncertainty Implementing 21st
Century Cures Act, LAw360 (Mar. 15, 2017, 12:11 PM), https://www.1aw360.com
/articles/900882/fda-faces-uncertainty-implementing-21st-century-cures-act.
31 Harlan M. Krumholz & Gregg Gonsalves, Taking A Ride on the NIH Budget
Rollercoaster, STAT (May 1, 2017), https://www.statnews.com/2017/05/01/nih-
budget-21st-century-cures-act/.
32 21st Century Cures Act, Pub. L. No. 114-255, § 2011, 130 Stat. 1033, 1047 (codified as
42 U.S.C. § 2 89g-5).
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general authority of the Secretary of HHS to foster rapid innovation
in this realm and also sets forth protections for human research
subjects and the data generated by research. 1 The Act lists five
components for the initiative, including "developing new
approaches for addressing scientific, medical, public health, and
regulatory science issues."34 The Secretary is also expressly required
to coordinate with the FDA to achieve the goals of the initiative. 35
Part III examines legislative provisions directly impacting the FDA.
C. MARKET TRAJECTORY FOR COMPANION DIAGNOSTICS
Precision medicine necessarily promises innovation not only in
the development of lifesaving drugs and biologics for diseases such
as cancer, but also in the companion diagnostic field. There is a
growing drive on the part of regulators, and entities within industry,
to partner drug and biologic development with a diagnostics test; the
companion diagnostics market is projected to grow globally from
$3.1 billion in 2014 to $8.7 billion in 2019.6 Partnering development
makes sense for industry, and regulators, as the companion
diagnostic serves as a safeguard for appropriate selection and use of
the drug or biologic. Co-development can assist with reducing costs
to consumers, in that they will not be paying for a drug that does not
work for them. Likewise, the certainty of particular drugs' efficacy
for individual patients will compliment current movements toward
33 21st Century Cures Act, Pub. L. No. 114-255, §§ 2011-14, 130 Stat. 1033, 1047-51
(codified as 42 U.S.C. § 2 89g-5 and amending §§ 241 and 282(b)).
-Id. § 2011.
3s Id.
3 Arundhati Parmar, Companion Diagnostics Market Set to Grow to $8.7B by 2019, MED.
DEVICE & DIAGNOSITC INDUS. (Sept. 8,2014), http://www.mddionline.com/article/
companion-diagnostics-market-set-grow-87b-2019.
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comparative effectiveness research and waste reduction in healthcare
reimbursement. It will also significantly reduce adverse events:
patients will not be prescribed drugs that will cause them harm
during the course of normal use. Of course, more personalization
means less pay-out for the pharmaceutical industry adhering to the
blockbuster drug model; however, it also presents an opportunity for
much-needed changes to industry approaches to research and
development.
Facilitating the growth of companion diagnostics will be next
generation sequencing, or NGS.37 NGS technologies do not rely on
conventional DNA sequencing using Sanger biochemistry methods,
they instead rely on various emerging high-throughput platforms. 38
These developments have dramatically reduced costs over the past
decade. Using current sequencing technologies, an individual
genome can be sequenced for approximately $1,000 - down from just
over $1 million in 2008. 39 However, many experts caution that
although NGS will enable scientists to "find many variants," these
3 The FDA has expressed that they are "committed to implementing a flexible and
adaptive regulatory oversight approach" for NGS in vitro diagnostics. See U.S. FOOD
& DRUG ADMIN., DRAFT GUIDANCE: USE OF STANDARDS IN FDA REGULATORY
OVERSIGHT OF NEXT GENERATION SEQUENCING (NGS)-BASED IN VITRO DIAGNOSTICS
(IVDS) USED FOR DIAGNOSING GERMLINE DISEASES 2 (July 8, 2016) [hereinafter NGS
IVD DRAFT GUIDANCE], https://www.fda.gov/downloads/medicaldevices/device
regulationandguidance/guidancedocuments/ucm509838.pdf.
m See Jay Shendure & Hanlee Ji, Next-generation DNA Sequencing, 26 NATURE BIOTECH.
1135, 1135 (2008).
39 The Cost of Sequencing a Human Genome, NATL INSTS. OF HEALTH, https://
www.genome.gov/sequencingcosts/ (last updated July 6, 2016) (Figure 1
approximates the 2008 cost to be higher than $1 million). The NIH notes that the
reduction in costs far exceeds those predicted by Moore's Law. Id.
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genetic variants "will not always be targets for particular disease."40
During a roundtable hosted by the Institute of Medicine, one
commenter offered that "[t]he sheer magnitude of the information
that we'll find on the genetic and molecular level is going to far
surpass our capacity to run clinical trials."4 ' Simply put, there will be
an ongoing challenge of separating the signal from the noise; NGS
may unleash a flood of genetic information without a clear answer
for what this information means for therapeutic efficacy and drug
response.
In an effort to foster research and discovery in this area, the FDA
has launched a website called PrecisionFDA, providing "a
community platform for NGS assay evaluation and regulatory
science exploration." 42 Deciphering information generated and
published on this crowd-sourced, cloud-based site will be integral to
biomarker identification, standard setting, clinical trial development,
and, ultimately, regulatory assessment and adaptability. Users have
already been challenged by the FDA to test accuracy and
reproducibility of software applied to genetic research through the
online portal, and to identify genetic variants within select datasets. 43
The FDA has also published draft guidance documents 44 and
4 SARAH H. BEACHY ET AL., INST. OF MED., REFINING PROCESSES FOR THE CO-
DEVELOPMENT OF GENOME-BASED THERAPEUTICS AND COMPANION DIAGNOSTICS:
WORKSHOP SUMMARY 17 (National Academies Press 2014) (quoting Walter Koch,
Roche Molecular Systems) [hereinafter IOM Workshop Summary].
4 Id. at 15 (quoting Felix Frueh, Third Rock Ventures).
42 FOOD & DRUG ADMIN., PRECISIONFDA, https://precision.fda.gov/docs/intro (last
visited Oct. 25, 2017).
4 Precision FDA Wraps Up Second Challenge, CLINICAL INFORMATICS NEWS, May 16,
2016, http://www.clinicalinformaticsnews.com/2016/5/19/precisionfda-wraps-up-
second-challenge.aspx
4 NGS IVD DRAFT GUIDANCE, supra note 37.
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discussion paperS 45 on analytical and clinical strategies to support
development of NGS diagnostic tests in the wake of the PMI.
As the FDA and the drug, biologic, and medical device industries
embark on research and development in precision medicine, existing
legal frameworks and processes provided by Congress and the FDA
provide a foundation for oversight. The next Part explores FDA
regulation of companion diagnostics and the accompanying drug or
biologic product.
II. FDA FRAMEWORKS FOR COMPANION DIAGNOSTICS
A companion diagnostic is characterized by the FDA as "a
medical device, often an in vitro device, which provides information
that is essential for the safe and effective use of a corresponding drug
or biological product." 46 Companion diagnostics may potentially
serve one or more purposes: identify patients who are most likely to
benefit from a particular therapeutic product; identify patients likely
to be at increased risk for serious side effects as a result of treatment
with a particular therapeutic product; or monitor response to
45 USE OF DATABASES FOR ESTABLISHING THE CLINICAL RELEVANCE OF HUMAN GENETIC
VARIANTS (Food & Drug Admin. Preliminary Discussion Paper, Nov. 13, 2015),
https://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConfe
rences/UCM467421.pdf; DEVELOPING ANALYTICAL STANDARDS FOR NGS TESTING
(Food & Drug Admin. Preliminary Discussion Paper, Nov. 12, 2015), https://www.
fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM4
68521.pdf; OPTIMIZING FDA's REGULATORY OVERSIGHT OF NEXT GENERATION
SEQUENCING DIAGNOSTIC TESTS-PREUMINARY DISCuSSION PAPER (Food & Drug
Admin. Preliminary Discussion Paper, 2014), https://www.fda.gov/downloads
/medicaldevices/newsevents/ workshopsconferences/ucm427869.pdf.
4 Companion Diagnostics, FOOD & DRUG ADMIN., http://www.fda.gov/Medical
Devices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297.htm (last
updated Oct. 5, 2016).
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treatment with a particular therapeutic product for the purpose of
adjusting treatment to achieve improved safety or effectiveness.47
Essentially, the device is the "companion" to the FDA-approved
drug or biologic.
The FDA has evaluated and approved companion diagnostics
using their drug, biologic and medical device authority. The drug or
biologic and the medical device (the companion diagnostic) must
gain separate FDA approval in order to enter the market. Distinct
statutory and regulatory provisions apply to each of these areas, and
the approval processes share similarities but are not uniform. New
drugs and new biologic products must undergo clinical
investigations and satisfy approval requirements, including full
reports of clinical investigations supporting the safety and efficacy of
the new product, labeling requirements, adherence to good
manufacturing practices, and mandated patent disclosures. 48 The
FDA must affirmatively approve the new drug or biologic product,
subject to robust statutory and regulatory procedures. Similarly,
medical devices categorized as companion diagnostics are subjected
to the FDA's highest risk classification, Class III pre-market approval
(PMA), which requires clinical trials, special controls, and
information on labeling, and manufacturing.49 This policy decision
rests on the position that because the companion diagnostic directs
the choice of drug or biologic that a patient ultimately receives, the
manufacturer must assure that it is safe and effective for that purpose
through clinical trials.5 0
47 Id.
4 See generally 21 U.S.C. § 355 and 42 U.S.C. § 262 (2016).
9 See generally, 21 U.S.C. §§ 360c, 360e (2016).
50 The medical device premarket approval process is distinguishable from the
premarket notification process (also known as the 510(k) clearance process). The
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The FDA requires a companion diagnostic test alongside a drug
"if a new drug works on a specific gene or biological target that is
present in some, but not all, patients with a certain cancer or
disease." 51 Successful co-development depends on a "thorough
molecular understanding of both the pathology and drug
mechanism of action." 52 FDA emphasizes that the approval process
works best when the test development begins prior to the drug
entering clinical trials, but also recognizes that may not always be
feasible.53
Ideally, a therapeutic product and its corresponding IVD [in
vitro diagnostic] CD [companion diagnostic] device should
be developed contemporaneously with the clinical
performance and clinical significance of the IVD CD device
established using data from the clinical development
program of the corresponding therapeutic product.
However, FDA recognizes there may be cases when
contemporaneous development may not be possible. An IVD
CD may be a novel IVD device, a new version of an existing
premarket notification process is available for lower risk medical devices that may
enter the market after demonstrating "substantial equivalence" to a predicate device
already on the market. Substantial equivalence means (a) that the device has the same
intended use and same technological characteristics as the predicate device or (b) has
the same intended use and a different technological characteristics but does not raise
novel safety and effectiveness questions and is at least as safe and effective as the
predicate device. 21 U.S.C. § 360c(i) (2012).
51 See Hand in Hand, supra note 16, at 2. Note that the FDA here uses the term "drug" -
the same reasoning applies to biological products as well.
52 Dana Olsen & Jan Trest Jorgensen, Companion Diagnostics for Targeted Cancer Drugs
- Clinical and Regulatory Aspects, 4 FRONT. ONCOL. 105 (2014).
53 See Hand in Hand, supra note 16, at 2.
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device by a different manufacturer, or an existing device
already cleared or approved for another purpose.5
The FDA has produced two guidance documents to inform the
development of companion diagnostics. However, FDA staff are
careful to emphasize that "[n]o two co-development programs are
the same" and thus early communications with the FDA are critical."
In August 2014 draft guidance, the FDA provides baseline
mechanisms for industry to identify the need for a companion
diagnostic at very early stages in drug development in order to allow
for successful integration and planning. 56 It also discusses a
requirement to coordinate labeling for co-developed products as a
means to provide patients with adequate directions for use." The
FDA released the second draft guidance on July 15, 2016, which is
intended as a practical guide to further assist drug and biologic
product sponsors and medical device sponsors in developing both a
therapeutic product and a companion diagnostic. 8
A recent drug and companion diagnostic tandem approved by
the FDA illustrates successful co-development between drug and
5 FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: IN VITRO COMPANION DIAGNOSTIC
DEVICES 7 (Aug. 6, 2014). [hereinafter IN VITRO COMPANION DIAGNOSTIC DEVICES]
5 IOM Workshop Summary, supra note 40, at 12 (quoting Elizabeth Mansfield,
Director of Personalized Medicine staff in Office of In Vitro Diagnostics and
Radiological Health).
- IN VrrRO COMPANION DIAGNOSTIC DEVICES, supra note 54, at 10-12.
5 "The use of an IVD companion diagnostic device with a therapeutic product is
stipulated in the instructions for use in the labeling of both the diagnostic device and
the corresponding therapeutic product, including the labeling of any generic
equivalents of the therapeutic product." IN VITRO COMPANION DIAGNOSTIC DEVICES,
supra note 54, at 7.
5 FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: PRINCIPLES FOR CODEVELOPMENT
OF AN IN VITRO COMPANION DIAGNOSTIC DEVICE WITH A THERAPEUTIC PRODUCT (July
15, 2016).
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medical device sponsors. The drug, Rydapt (midostaurin), is
indicated for use in adults with newly diagnosed acute myeloid
leukemia (AML) having the genetic mutation FLT3, in combination
with chemotherapy.5 9 New drug approval for the AML indication
was granted to Novartis through both priority review and
breakthrough therapy status.60 The approved diagnostic, called the
LeukoStrat CDx Mutation Assay, detects the relevant FLT3 mutation,
and was granted to Invivoscribe Technologies. 61 The FDA describes
the product as,
[A] PCR-based, in vitro diagnostic test designed to detect
internal tandem duplication (ITD) mutations and the
tyrosine kinase domain mutations D835 and 1836 in the FLT3
gene in genomic DNA extracted from mononuclear cells
obtained from peripheral blood or bone marrow aspirates of
patients diagnosed with acute myelogenous leukemia
(AML). The LeukoStrat@ CDx FLT3 Mutation Assay is used
as an aid in the selection of patients with AML for whom
RYDAPT (midostaurin) treatment is being considered.62
5 Press Release, FOOD & DRUG ADMIN., FDA APPROVES NEW COMBINATION
TREATMENT FOR ACUTE MYELOID LEUKEMIA (Apr. 28, 2017), https://www.fda.gov
/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm.
60 Id. Priority review and breakthrough therapy status will be discussed in Part III.
61 PMA Monthly Approvals 4/1/20174/30/2017, FOOD & DRUG ADMIN., https://
www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/Devic
eApprovalsandClearances/PMAApprovals/UCM556295.pdf.
62 Id. The FDA further provides that the diagnostic assay is only to be performed at a
single site laboratory in San Diego, CA. Id.
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III. RECENT LEGISLATIVE AND AGENCY ACTIVITY SUPPORTING
INNOVATION IN BIOMEDICAL REGULATION
Although only a few dozen companion diagnostic products have
been reviewed and approved by the FDA, the push toward precision
medicine assures that the FDA will continue to assess innovative
developments. While the existing regulatory framework is
functional, and continuously evolving based on the science, several
pieces of recent legislation provide additional authority and
flexibility to the FDA to refine the pathway to market. Many of these
provisions, including the breakthrough therapy status and biosimilar
approval pathway, have been integrated into the regulatory process
for companion diagnostics and the accompanying drug and biologic
products; others are in early implementation and development
stages. The FDA can draw from these authorities and frameworks as
they consider how best to design flexible and adaptive strategies for
regulation in the realm of precision medicine. This Part briefly details
this legislation, as well as the recent activity in the realm of laboratory
developed tests (LDTs).
A. THE AFFORDABLE CARE AcT OF 2010
The Patient Protection and Affordable Care Act (ACA) is
infamous for establishing the individual mandate for healthcare,
expanding Medicaid, introducing state health insurance exchanges,
ensuring health insurance for pre-existing conditions, and various
other substantial changes to health care law. However, the legislation
also created a significant new abbreviated approval process for
biological products. 63 A biological product is defined as a "virus,
- 42 U.S.C. § 262(k) (2012).
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therapeutic serum, toxin, antitoxin, vaccine, blood, blood component
or derivative, allergenic product, protein (except any chemically
synthesized polypeptide), or analogous product, or arsphenamine or
derivative of arsphenamine (or any other trivalent organic arsenic
compound), applicable to the prevention, treatment, or cure of a
disease or condition of human beings."' By statutory definition, a
biological product is distinct from a drug because of its source (as
biological rather than chemically synthesized), yet shares the
attribute of serving as a prevention, treatment, or cure. 65
The Biologics Price Competition and Innovation Act (BPCIA),
Title 7 of the ACA, sets forth a "biosimilar" 66 and "interchangeable"67
- 42 U.S.C. § 262(i).
6 Historically, the FDA oversees drugs through the Food, Drug and Cosmetic Act and
biologics through the Public Health Service Act. Biological products are often referred
to as biologic drugs.
66 The statute provides that biosimilarity means "(A) that the biological product is
highly similar to the reference product notwithstanding minor differences in clinically
inactive components; and (B) there are no clinically meaningful differences between
the biological product and the reference product in terms of .. . safety, purity, and
potency. ... " 42 U.S.C. § 262(i)(2). The biosimilar BLA (bBLA) must include analytical
studies, animal studies, and a clinical study or studies with the following
requirements: the biological product must have the same mechanism(s) of action for
condition(s) of use that have been previously approved for the reference product; it
must have the same route of administration, dosage form, and strength; and the
application must demonstrate that the facility assures the development of a "safe,
pure, and potent" product. 42 U.S.C. § 262(k)(2)(A)(i).
67 Interchangeability requires that the product is biosimilar and that the product "may
be substituted for the reference product without the intervention of the health care
provider who prescribed the reference product." 42 U.S.C. § 262(i)(3). Here, the
application must demonstrate an expectation to provide the "same clinical result as
the reference product in any given patient." 42 U.S.C. § 262(k)(4)(A)(ii). The
application must also show that when the biologic is "administered more than once to
an individual, the risk in terms of safety or diminished efficacy of alternating or
switching between use of the biological product and the reference product is not
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route to market for biologics, creates a twelve year exclusivity period
for biologic innovator products, one year exclusivity period for
interchangeable products, and introduces a complicated disclosure
process for industry dealing with patent rights. 68 Also included in the
ACA of potential relevance to precision medicine and companion
diagnostics are provisions aimed at incentivizing drug
development 69 and the creation of entities to examine comparative
effectiveness. 0
greater than the risk of using the reference product without such alteration or switch."
42 U.S.C. § 262(k)(4)(B).
6 This disclosure process is much different than the certification and disclosure
process contained in the generic drug approval legislation, or Hatch-Waxman Act. The
provisions have been attacked by industry and judges alike as unclear. The Supreme
Court granted certiorari in January 2017 in two cases involving the legislation. The
first, Amgen v. Sandoz asks "is an applicant required by 42 U.S.C. § 262(l)(2)(A) to
provide the reference product sponsor with a copy of its biologics license application
and related manufacturing information, which the statute says the applicant 'shall
provide;' and, where an applicant fails to provide that required information, is the
Sponsor's sole recourse to commence a declaratory judgment under 42 U.S.C. §
262(1)(9)(C) and/or a patent-infringement action under 35 U.S.C. § 271(e)(2)(C)(ii)?"
Docket No. 15-1195, SUP. CT. OF THE U.S. (Jan. 13, 2017), https://www.supreme
court.gov/qp/15-01195qp.pdf. The second, Sandoz v. Amgen, asks "[wihether notice of
commercial marketing given before FDA approval can be effective and whether, in
any event, treating § 262(1)(8)(A) as a standalone requirement and creating an
injunctive remedy that delays all biosimilars by 180 days after approval is improper."
Docket No. 15-1039, SUP. CT. OF THE U.S. (Jan. 13, 2017), https://www.supreme
court.gov/qp/15-01039qp.pdf. The two cases have been consolidated; oral arguments
were held April 26, 2017.
69 The Qualifying Therapeutic Discovery Project contained with the ACA gives tax
credit to pharmaceutical and biotech companies that treat unmet medical needs or
prevent, detect, or treat chronic or acute diseases and conditions; advance goal of
curing cancer; and reduce long-term health care costs in US. This tax credit applies
only to companies with 250 people or less and covers up to 50% of qualified
investment. 26 U.S.C. §48D (2016).
70 The ACA also establishes the Patient Centered Outcomes Research Institute
(PCORI), for the evaluation of health and medical technologies and products using a
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As a means to implement the new abbreviated approval process,
the FDA has formed a Biosimilar Implementation Committee co-
chaired by the Directors of CDER and CBER, installed a new Acting
Associate Director for Biosimilar within the Office of New Drugs
(OND), and created a Biosimilars Review Committee within CDER
to advise OND.' The FDA published three guidance documents for
industry in February 2012 (subsequently revised in 2015),72 a fourth
comparative effectiveness approach to clinical efficacy. 42 U.S.C. §1320e (2012). The
inclusion of PCORI reflects a movement toward the utilization of comparative
research to inform cost and reimbursement decisions. Many question the performance
of PCORI specifically but others see the approach appealing to the drug development
model. See, e.g., Fred Schulte, Is Obama's Research Institute Worth the Billions?, NAT'L
PUB. RADIO (Aug. 4, 2015), http://www.npr.org/sections/health-shots/2015/08
/04/428164731/is-obamacares-research-institute-worth-the-billions. One analyst
offers that a comparative effectiveness "process and decision-making algorithm will
boost innovation by allowing drug manufacturers to see what product features are
valued and rewarded and thereby give companies a better guidance to target
medication pipeline." Salil Parab, Impact of the Affordable Care Act on Pharmaceutical and
Biotech Industry, INST. FOR ADVANCED ANALYTICS, at 6, http://analytics.ncsu.
edu/sesug/2014/PH-08.pdf. Still others assert that the life science industry has been
negatively impacted by the ACA entirely. For example, Avalere Health projects that
the ten-year cost of the ACA on brand name pharmaceutical companies will be $105
billion, mainly from increased Medicaid rebates and net cost or discounts in the
Medicare drug coverage gap. J.M. Pickett, Supreme Court Rules for ACA, Leaving Pharma
Fees Intact, EXPERT BRIEFINGS (June 29, 2012), http://www.expertbriefings.com/news
/supreme-court-rules-for-aca-leaving-pharma-fees-intact/.
71 See Food & Drug. Admin., Implementation of the Biologics Price Competition and
Innovation Act of 2009, http://www.fda.gov/Drugs/GuidanceComplianceRegulatory
Infonnation/ucm2l5089.htm (last updated Feb. 12, 2016); see also, Jordan Paradise, The Legal
and Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May
Impact the U.S. Healthcare System, 41 AM. J. OF L. & MED. 49, 50 (2015).
7 See FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: BIOSIMILARS: QUESTIONS AND
ANSWERS REGARDING IMPLEMENTATION OF THE BIOLOGICS PRICE COMPETITION AND
INNOVATION ACT OF 2009 (Apr. 2015), https://www.fda.gov/downloads/drugs
/guidances/ucm444661.pdf; FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY:
BIOSIMILARS: QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A
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in May 2014,73 and a fifth and sixth in January 2017.74 The FDA also
unveiled its Lists of Licensed Biological Products with Reference Product
Exclusivity and Biosimilarity or Interchangeability Evaluations, or the
Purple Book, in September 2014. " The Purple Book identifies
innovator biological products approved by the FDA, including any
eventual biosimilar and interchangeable products. 6
REFERENCE PROTEIN PRODUCT (Apr. 2015), http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM291134.pdf;
FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SCIENTIFIC CONSIDERATIONS IN
DEMONSTRATING BIOSIMILARITY TO A REFERENCE PRODUCT (Apr. 2015), http://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM2911
28.pdf.
73 See FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CLINICAL PHARMACOLOGY
DATA TO SUPPORT A DEMONSTRATION OF BIOSIMILARITY TO A REFERENCE PRODUCT
(Dec. 2016), https://www.fda.gov/downloads/drugs/guidancecomplianceregulato
ryinformation/ guidances/ ucm397017.pdf.
74 FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: NONPROPRIETARY NAMING FOR
BIOLOGICAL PRODUCIS (Jan. 2017), http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatorylnformation/Guidances/UCM459987.pdf; FOOD &
DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY: CONSIDERATIONS IN DEMONSTRATING
INTERCHANGEABILITY WITH A REFERENCE PRODUCT (Jan. 12, 2017), http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/U
CM537135.pdf. The naming guidance document establishes that biosimilar products
will be given the drug's proper name followed by a hyphen and suffix for biosimilar
products. The suffix requires four lowercase letters that are unique and devoid of
meaning. For originator products, FDA will use the core name adopted by USAN.
There may be a prefix to distinguish a previously licensed biologic where FDA
determines necessary for public health (post-market surveillance, tracking, recall
ability). FDA is currently contemplating whether interchangeable products will
require a unique suffix.
FOOD & DRUG ADMIN., PURPLE BOOK: LISTS OF LICENSED BIOLOGICAL PRODUCTS WITH
REFERENCE PRODUCT EXCLUSIVITY AND BIOSIMILARIrY OR INTERCHANGEABILITY
EVALUATIONS, http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrug
sareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimi
lars/ucm411418.htm (last updated May 23, 2017).
76 The Purple Book operates as an information resource in much the same way that the
Orange Book does in the pharmaceutical context. However, unlike the Orange Book,
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Seven biosimilar products have been approved by the FDA, as
noted in Figure 1.7 7 Many other biosimilars are currently under
investigation by sponsors and the FDA. This quicker route to market
is sure to foster an increase in biologic sponsors willing to pursue
products with companion diagnostics.
Figure 1: FDA-Approved Biosimilar Products
Approval Product & Proper Name Innovator
Company Product
3/6/15 Zarxio Filgrastim Neupogen
(Sandoz) -sndz (Amgen)
4/5/15 Inflectra Infliximabd Remicade
(Celltrion) -dyyb (Janssen)
8/30/16 Erelzi Etanercept Enbrel
(Sandoz) -szzs (Amgen)
9/23/16 Amjevita Adalimumab Humira
(Amgen) -atto (Abbvie)
4/21/17 Renflexis Infliximabd Remicade
(Samsung -abda (Janssen)
Bioepis)
8/25/17 Cyltezo Adalimumab Humira
(Boehringer -adbm (Abbvie)
Ingelheim)
9/14/17 Mvasi Bevacizumab Avastin
(Amgen) -awwb (Genentech)
the Purple Book does not contain patent information, a reflection of the novel patent
process laid out in the BPCIA.
7 This is the number of approved biosimilar products as of September 28, 2017. The
FDA has not yet approved an interchangeable product.
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B. THE FOOD AND DRUG ADMINISTRATION SAFETY AND
INNOVATION ACT OF 2012
Two years later, Congress passed the Food and Drug
Administration Safety and Innovation Act (FDASIA), which, among
other things, establishes a statutory process for FDA review of
breakthrough therapies.78 The FDA defines a breakthrough therapy
as a drug
intended alone or in combination with one or more
other drugs to treat a serious or life threatening
disease or condition and preliminary clinical
evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on
one or more clinically significant endpoints, such as
substantial treatment effects observed early in
clinical development.7 9
The provisions create an expedited review mechanism and
mandatory timeframes for the FDA to respond to requests for
breakthrough therapy designation for either drugs or biologics. FDA
published a guidance document in May 2014 detailing the process
for industry. 0 The breakthrough therapy designation joins existing
pathways for expedited review at the FDA set forth either through
legislation or FDA regulation, including Fast Track designation,
7 Food & Drug Admin. Safety & Innovation Act, Pub. L. 112-144, 126 Stat. 993 (2012)
(codified in title 21 the U.S.C.). Breakthrough therapy status signals that the drug is
progressing through clinical trials subject to the statutory provisions provided for
breakthrough therapies, not that the drug has been approved by the FDA.
- Pub. L. 112-144, § 902, 126 Stat. 1086.
8 FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: EXPEDITED PROGRAMS FOR SERIOUS
CONDITIONS - DRUGS AND BIOLOGICS (May 2014), http://www.fda.gov/downloads
/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/UCM358301.pdf.
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accelerated approval, and priority review designation.8 1 Notably, of
the breakthrough therapy designations granted by the FDA in the
first year after FDASIA, two-thirds include a companion diagnostic.82
This designation further incentivizes investments in precision
medicine.
C. THE 21sT CENTuRY CUREs ACT OF 2016
The first version of the 21st Century Cures Act was introduced
to the United States House of Representatives on May 19, 2015,83 and
unanimously approved by the House Energy and Commerce
Committee two days later.8 It passed the full House on July 10, 2015,
but died in committee in the Senate." The major purpose was "to
speed up the pace at which FDA approves new medicines" and
included topics such as matters affecting the regulation of
pharmaceuticals, medical devices, and biotechnology products. 8
The bill was championed by both industry and patient advocates
because it was viewed as an accumulation of ideas to improve drug
8 A table within the FDA's breakthrough therapy guidance document compares the
four expedited mechanisms. Id., at 11.
82 Alexander J. Varond, Trends in Personalized Medicine, REGULATORY FOcus (Oct. 2013),
at 2, http://www.raps.org/WorkArea/DownloadAsset.aspx?id=5275.
8 H.R. 6, 114th Cong. (2015), https://www.congress.gov/bill/114th-congress/house-
bill/6.
8 Jeannie Baumann, House Energy/Commerce Unanimously OKs Bill That Would Amend
HIPAA Privacy Rule, PRIVACY LAW WATCH (BNA), May 26, 2015, at 1.
8 H.R. 6, 114th Cong. (2015).
86Alexander Gaffney, Regulatory Explainer: The (Updated) 21st Century Cures Act, REG.
AFF. PROF. Soc'Y (Apr. 30, 2015), http://www.raps.org/Regulatory-Focus/21st-
Century-Cures-Act/.
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development.8 7 The Act was divided into three distinctive sections:
discovery, development, and delivery.
Title I regarding discovery included increases to the NIH budget,
prize competitions, and administrative provisions; researcher grant
increases, capstone awards, and loan repayment for young scientists;
facilitation of collaborative research, including standardization of
data at the website www.clinicaltrials.gov, sharing and use of clinical
trial health data for research; pediatric research promotion; and
creation of the Council for 21st Century Cures, a nonprofit, public-
private partnership to accelerate discovery, development, and
delivery in innovative cures, treatments and preventative
measures.88
Title II regarding development was largely focused on drug,
biologic, and medical device regulation. It included provisions for
patient-focused drug development, incorporating patient experience
data into risk-benefit assessment frameworks; qualification of drug
development tools and accelerated approval development plans;
advancement of precision medicine on the part of the FDA, requiring
periodic guidance on precision medicine development and
accelerated approval; modem trial design and evidence
development; antibiotic drug development provisions; orphan
product extensions of exclusivity; requirement of final guidance from
FDA on combination product responsibilities; breakthrough
designation for medical devices; allowance of third party quality
assessment for medical devices; allowance of the recognition of
8 The bill was described as a "Christmas tree" and "moonshot opportunity for lots of
stuff." Darius Tahir, Lobbying Groups Eye Fast Moving FDA Bill, MOD. HEALTHCARE
(May 16, 2015), http://www.modernhealthcare.com/article/20150516/MAGAZINE
/305169956/lobbying-groups-hungrily-eye-fast-moving-fda-overhaul-bill.
8 H.R. 6, 114th Cong. (2015).
Imaged with Permission of N.Y.U. Journal of Law & Liberty
699
New York University Journal of Law & Liberty [Vol. 11:672
medical device standards; reduction of regulatory burden for some
Class I and II devices; expansion of the humanitarian device
exemption patient population; and a requirement for HHS and the
FDA to harmonize regulations governing human subjects research."
Title III would have amended the Public Health Service Act,
Social Security Act, and the Health Information Technology for
Economic and Clinical Health Act to address such topics as
interoperability; telehealth under Medicare; disposable medical
technologies; local coverage decision reforms; Medicare site-of-
service transparency; Medicare Part D patient safety and drug abuse
prevention; and various Medicaid, Medicare, and other reform,
including exclusion of authorized generics from calculation of
average manufacturer price, and civil money penalties for violations
related to grants, contracts, and other agreements.90
Funding was a large issue voiced by legislators because of the
Act's approximately $13 billion price tag.91 A news article by Ropes
& Gray LLP stated that a key issue discussed at the House Energy
and Commerce Committee's hearing was "the need for additional
FDA funding to support and implement the legislative proposals." 92
Critics of the first version of the legislation, including the former FDA
comnuissioner, Margaret Hamburg, worried that the Act's promise to
make medications and devices available to the public faster while
8 Id.
9 Id.
9 Steven Ross Johnson, 21 Century Cures Bill Progress Hits Possible Funding Roadblock,
MOD. HEALTHCARE (May 20, 2015), http://www.modernhealthcare.com/article/
20150520/NEWS/150529984.
92 Ropes & Gray LLP, Progressing Toward a Cure: House Committee Unveils Revised,
Streamlined 21st Century Cures Discussion Draft 3 (2015), https://www.ropesgray
.com/news-and-insights/Insights/2015/May/Progressing-Toward-a-Cure-House-
Committee-Unveils-Revised-Streamlined-21st-Century-Cures-Discussion.aspx.
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also reducing the cost of product development could "heighten the
risk of patients being exposed to inadequately tested and potentially
harmful products."9
The bill was then reintroduced, overhauled, and quickly gained
support from professional organizations, lobbyists, and the
pharmaceutical industry. Many of the provisions from the previous
bill were retained, but much was parsed into the bill from other
sources. The bill passed the House and Senate, with only five
Senators voting against it; at least one Senator cited objections to the
influence of the pharmaceutical industry.94 In its final form, signed
by President Obama in December 2016, the legislation spans several
hundred pages, covering myriad topics impacting health and
medical care across 18 titles.95 Relevant to this article, the legislation
provides several significant changes to the law, and to the FDA's
authority to oversee life science products.
First, the legislation specifically advances Precision Medicine,
tasking the Secretary of HHS with developing new approaches,
coordinating with other federal agencies, and ensuring the protection
of human participants in research.9 6 With regard to clinical trials and
participant information, the HHS is directed to issue certificates of
confidentiality to researchers receiving federal funding, which
prohibits those researchers from disclosing identifiable information
except in certain circumstances (including consent and when
necessary to treat the individual), grants immunity to this
93Steven Ross Johnson, FDA Reform Bill Criticized, MOD. HEALTHCARE (Apr. 11, 2015),
http://www.modernhealthcare.com/article/20150411/MAGAZINE/304119959
9 Jennifer Steinhauer & Robert Pear, Sweeping Health Measure, Backed by Obama, Passes
Senate, N.Y. TIMES, Dec. 8,2016, at A17.
95 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033 (2016).
96 Id. at § 2011.
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identifiable information from the legal process, 97 and allows the
Secretary to exempt individual biomedical research data from
disclosure where it is identifiable or could possibly be used to
identify.9 8 The Director of NIH is also authorized to require grant
recipients to share data generated from federally-funded research in
a manner consistent with federal law.99
Second, the legislation directs the FDA to make changes in a
number of areas for drug and medical device oversight. Figure 2
identifies the major provisions of the 21st Century Cures Act
impacting the FDA. Taken together, these provisions introduce
potentially significant changes to the FDA processes involved in
product review and approval of drugs, biologics, and medical
devices and give much discretion to the FDA to determine how to
implement particular requirements. Several provisions will
undoubtedly impact drug, biologic, and companion diagnostic
development, including the inclusion of patient experience data"
with drug approvals, new review mechanisms for use of
biomarkersll in clinical trial design for new drugs, use of real world
9 Id. at § 2012.
98 Id. at § 2013.
99 Id. at § 2014.
10 Patient experience data is defined as data that "are collected by any persons
(including patients, family members and caregivers of patients, patient advocacy
organizations, disease research foundations, researchers, and drug manufacturers)"
and "are intended to provide information about patients' experience with a disease or
conditions, including - (A) the impact of such disease or condition, or a related
therapy, on patients' lives; and (B) patient preferences with respect to treatment of
such disease or condition." Id. at § 3001.
101 A biomarker is defined as "a characteristic (such as a physiologic, pathologic, or
anatomic characteristic or measurement) that is objectively measured and evaluated
as an indicator of normal biologic processes, pathologic processes, or biological
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evidence 102 for support of new drug indications, allowance of
centralized institutional review board (IRB) reviews for medical
devices, 103 and the creation of a breakthrough medical device
category. 104
The legislation provides momentum to long-standing efforts to
reconstruct FDA's regulatory approach to novel and emerging
technologies. While it does not introduce drastic mandates to the
FDA to change its existing regulatory frameworks, it does challenge
them to consider and integrate more diverse source of information,
data collection, and methods of risk assessment in the context of
product review and approval.
Figure 2: Select 21st Century Cures Act Provisions Directed to the FDA
Section Overview
------- Subpart A: Patient-Focused Drug Development
3001 FDA required to include patient experience data statement at
time of drug approval.
3002 FDA required to issue guidance on methods of collecting
patient experience data.
3003 FDA exempted from Paperwork Reduction Act when
requesting patient information related to patient experience
data.
3004 FDA required to report on their review of patient experience
data.
-------- Subpart B: Advancing New Drug Therapies
responses to a therapeutic intervention." 21st Century Cures Act, Pub. L. No. 114-255,
§ 3011(a), 130 Stat. 1033, 1088-89 (2016).
102 Real world evidence is defined as "data regarding the usage, or the potential
benefits or risks, of a drug derived from sources other than randomized clinical trials."
Id. at § 3022.
1o3 Id. at § 3056.
10 Id. at § 3051.
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105 The Act defines "regenerative medicine therapy" as including "cell therapy,
therapeutic tissue engineering products, human cell and tissue products, and
combination products using any such therapies or products, except for those regulated
solely under section 361 of the Public Health Service Act and part 1271 of title 21, Code
of Federal Regulations." Id. at § 3033.
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3011 Creates review mechanism at FDA for biomarkers and other
drug development tools.
3012 Addresses FDA authority over genetically targeted drugs for
rare diseases.
3013 Reauthorizes pediatric rare drug disease priority review
voucher program.
3014 Requires GAO study on priority review programs regarding
impact on drug development.
3015 Allows grants for observational studies for orphan drug
development program.
3016 FDA may issue grants for study of continuous manufacturing
for drugs.
------- Subpart C: Modern Trial Design & Evidence Development
3021 FDA required to hold public meeting and issue guidance on
adaptive designs and statistical modeling for new drug
applications.
3022 FDA required to evaluate use of real world evidence to
support new indication of approved drug or post-market
requirements.
3023 HHS required to harmonize Common Rule and FDA
regulations; revises IRB processes where multiple sites.
3024 FDA may waive or alter informed consent for minimal risk
clinical trials.
------ Subpart D: Patient Access to Therapies & Information
3031 FDA may rely on qualified data summaries to support new
indication for approved drug.
3032 Companies must make compassionate use policies publicly
available.
3033 FDA may grant accelerated approval for regenerative
therapeutics. 05
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3034 Devices for use with regenerative therapeutic are deemed
moderate risk, unless Secretary determines higher risk.
3035 FDA required to update regulations and guidance on
regenerative therapeutics, hold public meeting.
3036 FDA required to consult with NIST and stakeholders to
establish regenerative medicine standards and support
development.
3037 Scope of permissible communications of health care economic
information.
3038 FDA required to meet with sponsors of combination products
early in process to agree to plan; clarifies dispute resolution
I among the Centers; reporting.
------- Subpart E: Antimicrobial Innovation & Stewardship
3041 FDA and CDC required to report on human resistance to
antimicrobial drugs.
3042 FDA may approve antimicrobial drugs based on limited
populations where treats life-threatening condition; labeling
to identify limited population study; review and approval of
promotional materials 30 days prior.
3043 Subpart E provisions impose no restrictions on prescribing or
practice of health care.
3044 FDA may rely on third party experts when issuing guidance
on use and indications.
------ Subpart F: Medical Device Innovations
3051 Creates new breakthrough medical device pathway to market.
3052 FDA may apply HDE exemption for devices for conditions
affecting 8,000 individuals.
3053 Creates process for use of standards in medical device review.
3054 FDA required to update lists for Class I and II device
regulation.
3055 Revises FDA medical device panel review process.
3056 Allows medical device sponsors to use central, rather than
local, TRB.
3057 FDA required to update guidance on CLIA waivers.
3058 FDA required to consider least burdensome means for
showing reasonable assure of safety and effectiveness.
3059 Emphasizes cleaning and validation data requirements for
reusable devices.
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3060 Sets forth five types of medical software that are not subject to
FDA regulation as a medical device, unless there is a safety
concern.
D. FDA AND LABORATORY DEVELOPED TEsTs
FDA policy decisions will also influence precision medicine and
product development. One area in which this is unfolding is
laboratory developed tests (LDTs). LDTs fall within the spectrum of
products categorized by the FDA as medical devices subject to either
premarket review or clearance, along with other substantive
requirements. The FDA defines an LDT as "an in vitro diagnostic
(IVD) that is intended for clinical use and designed, manufactured,
and used in a single laboratory." 10 6 IVD products are "reagents,
instruments, and systems intended for use in the diagnosis of disease
or other conditions, including a determination of the state of health,
in order to cure, mitigate, treat, or prevent disease or its sequelae." 107
The FDA has historically not enforced premarket review (or
clearance) and regulatory requirements for LDTs because they have
been relatively simple laboratory tests available on a limited basis.108
106 FOOD & DRUG ADMIN., DRAFr GUIDANcE: FDA NOTiFICATION AND MEDICAL DEVICE
REPORTING FOR LABORATORY-DEVELOPED TESTS (LDTs) 4 (2014), http://www.fda.gov
/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments
/UCM416684.pdf. Clinical use is defined by FDA regulations in terms of objective
intent of the person legally responsible for labeling the device and can be based on
aspects such as labeling claims, advertising, oral and written statements by the person
or representatives, and particular circumstances. Specifically, intent may be found if
the device "is, with the knowledge of such persons or their representatives, offered or
used for a purpose for which it is neither labeled nor advertised." 21 C.F.R. § 201.128
(2016).
10 21 C.F.R. § 809.3 (2016).
108 The Centers for Medicare and Medicaid Services also has overlapping regulatory
authority over in vitro diagnostics under the Clinical Laboratory Improvement
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However, following a July 2014 Notice of Intent to Congress, the FDA
released its Framework for Regulatory Oversight of Laboratory Developed
Tests (LDTs) in October 2014.109 Ending decades of enforcement
discretion, the FDA guidance highlights the inherent risk of certain
LDTs and announced its plan to subject products to medical device
requirements. 110 The guidance explicitly sets forth that high risk
LDTs will be regulated as medical devices subject to premarket
review and approval. 11 The FDA cites changed technological
capabilities and the proliferation of advanced marketing and
business models as the primary motivation for the change in
policy.11 2 On its website, the FDA emphasizes " [s]ome LDTs are now
more complex, have a nation-wide reach and present higher risks.""13
In addition, the FDA guidance specifically flagged problems with
product claims unsupported with adequate evidence and lack of
appropriate controls.114
Amendments (CLIA). See Clinical Laboratory Improvement Amendments, FOOD & DRUG
ADMIN., https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/IV
DRegulatoryAssistance/ucml24105.htm (last updated Sept. 29, 2017). . CLIA applies
to clinical laboratories that test patient specimens, assuring analytical validity and
reliability in the test results.
109 FOOD &DRUGADMIN., DRAFT GUIDANCE: FRAMEWORK FOR REGULATORY OVERSIGHT
OF LABORATORY-DEVELOPED TESTS (LDTS) (2014), http://www.fda.gov/downloads/
MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments
/ UCM416685.pdf [hereinafter LDT FRAMEWORK].
110 Id. at 7-11.
i ld. at l3.
112 Id. at 7-8.
11 Zika Virus Diagnostic Development, U.S. FOOD & DRUG ADMIN., http://www.fda.gov
/ EmergencyPreparedness/ Counterterrorism/ MedicalCountermeasures/MCMIssue
s/ucm494615.htm. (last updated Aug. 21, 2017).
114 LDT FRAMEWORK, supra note 109, at 9-10.
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The FDA has engaged with stakeholders following the
publication of the draft guidance. The FDA hosted a public workshop
in January 2015 to vet the framework and has collected public input
throughout the process.1 1 5 The FDA's flurry of activity has garnered
significant legal blog coverage; "6 opposing views on the LDT
framework were also published in JAMA. 1" In March 2015, an
independent group of clinical laboratories and diagnostic
manufacturers publicly responded to the FDA's position and framed
an alternative proposal. " Many other professional stakeholders
shared feedback as well, including the College of American
Pathologists, the Association for Molecular Pathology, and the
American Clinical Laboratory Association.' 19
Surprisingly, although likely a result of the impending
Administration change, the FDA announced on January 13,2017, that
they would not issue final guidance, at the urging of stakeholders to
seek more input and continue dialogue in this area. The FDA
I's Public Workshop - Framework for Regulatory Oversight of Laboratory Developed Tests
(LDTs), U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medicaldevices/news
events/workshopsconferences/ucm423537.htm. (last updated Jan. 23, 2015)
[hereinafter Public Workshop].
116 E.g., Jamie Wolzon et al., FDA Formally Issues Draft LDT Guidance; Provides 120 Day
Comment Period and Will Host October Public Meeting, FDA LAwBLOG (Oct. 2, 2014),
http://www.fdalawblog.net/fda law blog-hymanphelps/2014/10/fda-formally-
issues-draft-ldt-guidance-documents-provide-120-day-comment-period-and-will-
host-octobe.html; Jamie Wolzon, LDT Battle Lines Drawn, FDA LAWBLOG (Nov. 24,
2014), http://www.fdalawblog.net/fda_1aw-blog-hyman-phelps/2014/11/ldt-bat
tie-lines-drawn-fda-announces-jan-8-9-public-meeting-on-ldt-framework-lab-and-
medical-groups-.html.
117 James P. Evans & Michael S. Watson, Viewpoint, Genetic Testing and FDA Regulation:
Overregulation Threatens the Emergence of Genomic Medicine, 313 JAMA 669-70 (2015).
11 Diagnostic Test Working Group, A Proposed Regulatory Framework for In Vitro Clinical
Tests (2015), http://www.fdalawblog.net/DTWG-final-proposal.pdf.
119 Public Workshop, supra note 115.
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simultaneously issued a discussion paper.1 20 In the discussion paper,
FDA reports they
[a]nalyzed more than 300 sets of comments on the draft
guidances and discussion from a subsequent public
workshop held in 2015 as well as engaged in many meetings
and conferences with various stakeholders. In the absence of
issuing final guidance and at the request of stakeholders, we
feel it is our responsibility to share our synthesis of all the
feedback we have received, with the hope that it advances
public discussion on future LDT oversight. 12 1
The FDA noted that a "complementary approach [of both FDA
and CMS] in some form is supported by the broadest array of
stakeholders."1 22 Emphasizing that the discussion paper was only a
possible approach synthesized from public feedback, the FDA did
urge a prospective oversight framework based on a number of core
elements. These elements included a process of grandfathering
previously marketed LDTs; utilizing risk-based, phased-in oversight;
complementary evidence standards of FDA and CMS for clinical and
analytical validity; availability of third party review; collaboration
with the LDT community, including efforts to develop standards for
use; transparency of information; flexibility in product modification
without undue burden to industry; and quality system requirements
and inspections; and postmarket surveillance. 123
120 FOOD & DRUG ADMIN., DISCUSSION PAPER ON LABORATORY-DEVELOPED TESTS
(LDTS) (2017), http://www.fda.gov/downloads/MedicalDevices/ProductsandMed
icalProcedures/InVitroDiagnostics/LaboratoryDevelopedTests/UCM536965.pdf.
121 Id. at 2.
122 LDT FRAMEWORK, supra note 109, at 2.
123 LDT FRAMEWORK, supra note 109.
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Current uncertainty in LDT regulation has implications for
companion diagnostic research and development. Even where a
diagnostic assay is utilized solely to inform individual patient care
and is developed in-house (with no intent to commercialize the
product), FDA's current position is that its use to detect genetic status
is well within the bounds of the agency's medical device authority
under the statute. The lack of clarity over LDT regulation may stifle
companion diagnostic innovation or at the least cause confusion for
sponsors.
CONCLUSION
Precision medicine faces regulatory challenges, as does any emerging
area of science and innovation. Many of these challenges have
already been identified, others have yet to be confronted. As industry
and the FDA move forward, there are also ample opportunities for
collaboration, information-sharing, and new approaches. The FDA's
PrecisionFDA website is currently facilitating aggregation and
comprehension of data generated by genomic sequencing
advancements. The FDA has approved drug and companion
diagnostic products using breakthrough therapy status, and in May
2017 approved a new indication for a biologic drug based on a
biomarker. 124 Drug, biologic and medical device sponsors, once
operating as distinct industries, are actively working together to
124 On May 23, 2017, the FDA announced approval of the biologic Keytruda
(pembrolizumab) "based on a common biomarker rather than the location in the body
where the tumor originated." Press Release, Food & Drug Admin., FDA Approves
First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature (May 23,
2017), https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560
167.htm.
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develop products. And federal infrastructure has been put into place
to support continuing innovation in precision medicine. Perhaps
these are the proper conditions to spur FDA leadership to embrace
more adaptive, flexible, and dynamic regulation that transcends the
silo effect of traditional regulatory categories.1 25
125 See, e.g., Scott Gottlieb, FDA Needs to Change How It Regulates Novel Technologies,
FORBES (Jan. 12, 2016), https://www.forbes.com/sites/scottgottlieb/2016/01/12/
fda-needs-tochange-how-it-regulates-novel-technologies/#lbeb6ll6l9le (writing
about the need for the FDA to rethink its silo approach for the regulation of novel
technologies).
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